XENE (Xenon Pharmaceuticals) Total Operating Expense: $412.66 Mil (TTM As of Mar. 2026)


XENE Xenon Pharmaceuticals Inc XENE
25 GF Score
Price $60.30
! 5 Warning Signs
View Full Analysis

What is Xenon Pharmaceuticals Total Operating Expense?

Xenon Pharmaceuticals XENE -0.10% 25 Total Operating Expense is $412.66 Mil as of Mar. 2026. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Xenon Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $112.33 Mil. Xenon Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $412.66 Mil.

Xenon Pharmaceuticals Total Operating Expense Related Terms

Xenon Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Xenon Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenon Pharmaceuticals Total Operating Expense Chart

Xenon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.43 138.58 214.05 279.30 380.57

Xenon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.24 94.23 96.34 109.77 112.33
XENE
25GF Score
Xenon Pharmaceuticals Inc XENE
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenon Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $412.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $412.66 Mil mean?
Xenon Pharmaceuticals (XENE) has a Total Operating Expense of $412.66 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Xenon Pharmaceuticals and its competitors.
Is Xenon Pharmaceuticals' Total Operating Expense too high?
Xenon Pharmaceuticals' current Total Operating Expense is $412.66 Mil. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' Total Operating Expense compare to DFTX and LEGN?
Xenon Pharmaceuticals' Total Operating Expense of $412.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Xenon Pharmaceuticals and its competitors. Xenon Pharmaceuticals's current Total Operating Expense is $412.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current Total Operating Expense of $412.66 Mil. The current Total Operating Expense is $412.66 Mil. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current Total Operating Expense is $412.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xenon Pharmaceuticals Business Description

Other Exchanges XP0:Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score

Get the complete analysis for XENE

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$60.30
Price